Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

Eli Lilly’s once-daily weight loss pill succeeds in latest trial, paving the way for global approval

Lilly said it plans to ask regulators to approve the drug by the end of 2025.

Euronews

‘Gutted’: UK users of weight loss jab Mounjaro devastated by planned price hike

People using the jab reported positive results, but many say the increased cost will be prohibitively expensive, and they expect to put the weight back on when they stop

The Guardian - UK

Mounjaro users in UK warned against bulk buying before autumn price rise

Cost may increase as much as 170% from September, but patients warned against a quick switch to Wegovy

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

UK Sales of Wegovy Skyrocket 2,000% as Dieters Dump Mounjaro After 170% Price Hike

This trend drove WeGovy sales to jump 27 times higher — a 2,660% increase — on Wednesday compared with the typical daily average last month.

International Business Times UK

The Saturday Spread: 3 Beaten-Down Stocks That Are Potentially Poised for a Recovery (V, LLY, ABNB)

Although the market has been uncomfortably choppy in recent sessions, this is also the time for contrarians to pick up hot securities on the cheap.

Barchart

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Benzinga

Serena Williams reveals GLP-1 treatment helped her lose 31 pounds after giving birth

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam champion turned to a GLP-1 medication.

Euronews

Read news from The Economist, FT, and more,
with one subscription

Wegovy sales spike after maker of rival Mounjaro ramps up UK price

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

Evening Standard

Sales of Wegovy weight loss jabs soar 27-fold after rival Mounjaro ramps up price in UK

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication

The Independent UK

Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets

The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.

MarketBeat

Novo Nordisk Freezes Hiring As Wegovy Faces Copycats

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).

Benzinga

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Benzinga

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

International Business Times UK

Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks

Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

Benzinga

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

On Tuesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Barchart

2 Outstanding ‘Strong Buy’ Stocks to Grab in August

These two stocks offer a rare combination of income and growth.

Evening Standard

Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?

Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Weight loss drugs: how will you be affected by the Mounjaro price rise in the UK?

We’d like to hear from people who are taking Mounjaro and how they feel about the increase in cost for doses

Benzinga

Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond

Eli Lilly And Co.‘s (NYSE:LLY) recent, and highly unusual, issuance of a 40-year bond is fueling speculation that the pharmaceutical giant may be preparing for a major acquisition, with Viking Therapeutics Inc. (NASDAQ:VKTX) emerging as a potential target.

The Independent UK

Patients switch to Ozempic en masse as Mounjaro hikes prices

IN FULL

The Independent UK

Christopher Biggins latest celebrity to confirm he is using weight loss jabs

Actor and television personality Biggins, 76, is taking Eli Lilly jab Mounjaro

The Independent UK

Ozempic sales surge ‘up to 600%’ after Mounjaro price rises

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to 'almost as good' competitor

International Business Times UK

Ozempic Lawsuit: Patients Claim Life-Threatening Side Effects As Safety Questions Put Zepbound In The Spotlight

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh evidence.

The Independent UK

Voices: Pricing people out of using Mounjaro would be bad news for the NHS

COMMENT: The astronomical rise in weight-loss drug prices caused by Trump’s tariffs could have a significant – and dangerous – impact on Britain’s pharmacies and patients, writes Leyla Hannbeck, CEO of the Independent Pharmacies Association

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.